An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders

Bennie, M. and Black, C. and Cairns, V. and Hems, S. and Mciver, L. and Nicholson, J. and Oduro, S. and Payne, R. and Ramsay, W. (2009) An investigation of the Scottish medicines consortium (SMC) impact on and engagement with stakeholders. Basic and Clinical Pharmacology and Toxicology, 105 (Supp.1). p. 92. ISSN 1742-7835 (https://doi.org/10.1111/j.1742-7843.2009.00437.x)

Abstract

A poster presentation on the Scottish medicines consortium. SMC advises NHS Scotland about the status of newly licensed medicines, new formulations of existing medicines and new indications for established products. An investigation was undertaken to identify how SMC has impacted on NHS board Area Drug and Therapeutics Committees (ADTCs) in their assessment of new medicines, and the views of key stakeholders (ADTCs, public partners and pharmaceutical industry).

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Item metadata

  Item type:	Article
  ID code:	31762
  Dates:	Date Event August 2009 Published 26 June 2009 Published Online
  Subjects:	Medicine > Pharmacy and materia medica
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
  Depositing user:	Pure Administrator
  Date deposited:	23 Jun 2011 10:11
  Last modified:	08 Apr 2024 19:13
  URI:	https://strathprints.strath.ac.uk/id/eprint/31762